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Background: Circulating angiotensin II (AngII) is elevated in congestive heart failure (CHF), and leads to skeletal
muscle wasting, which is strongly associated with poor patient outcomes. We previously found that AngII
upregulates protein phosphatase 2C-alpha (PP2Cα) and dephosphorylates AMP-activated protein kinase (AMPK), a
critical regulator of cellular metabolism, in skeletal muscle.
Methods: To determine the role of PP2Cα in AngII-induced wasting, gastrocnemius (Gas) muscles of FVB mice were
injected with scrambled or PP2Cα siRNA and mice were infused with saline or AngII for 4 days.
Results: Knockdown of PP2Cα reduced AngII wasting, blocked AngII upregulation of PP2Cα, increased p-T172-AMPK,
and inhibited AngII-mediated reductions in peroxisome proliferator-activated receptor-γ coactivator-1α (PGC-1α),
nuclear respiratory factor 1 (NRF1), mitochondrial transcription factor A (TFAM), in complex IV activity, and in ATP levels.
AngII impaired the rate of autophagy as determined by a 2.4-fold increase in p62/SQSTM1 (p62) accumulation. This
induction was reduced by PP2Cα knockdown, which also increased beclin-1 expression and microtubule-associated
protein 1 light chain 3 (LC3)-II conversion in AngII-infused Gas. AngII reduced activating S555 phosphorylation of
UNC-51-like kinase 1 (ULK1), a critical regulator of autophagosome formation, and increased inhibitory S757 ULK1
phosphorylation and these effects were prevented by PP2Cα siRNA.
Conclusions: AngII inhibited AMPK activity and reduced PGC-1α and TFAM expression (thereby inhibiting mitochondrial
biogenesis) and impaired ULK1 activation and autophagy (thereby also inhibiting clearance of damaged mitochondria),
resulting in mitochondrial dysfunction, decreased ATP, and wasting. Knockdown of PP2Cα normalized AMPK activity,
PGC-1α, NRF1, and TFAM levels and blocked AngII inhibition of ULK1, leading to improved mitochondrial biogenesis/
recycling/function, energy production, and inhibition of AngII-induced wasting. These results demonstrate novel effects
of AngII on cellular metabolism that are likely critical in mediating the muscle wasting that is a hallmark of CHF.
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In conditions such as congestive heart failure and chronic
kidney disease, where loss of lean body mass correlates
strongly with poor prognosis [1-3], circulating angiotensin
II (AngII) is elevated, and is a likely major contributor to
skeletal muscle wasting associated with these diseases.
Indeed, we have shown that AngII infusion in rodents in-
duces muscle atrophy which is related to multiple mecha-
nisms including activation of the ubiquitin proteasome
pathway (UPP) [4,5], inhibition of the insulin/IGF-1/Akt/
mammalian target of rapamycin (mTOR) axis [5-13],
reduction in appetite [14-16], and activation of apoptosis
[10,17]. The effects of AngII include indirect effects via
circulating mediators [6,13,18-22] and direct effects to
reduce regeneration [16,23].
While it has been well established that AngII causes
skeletal muscle atrophy, much less is known about the
metabolic and bioenergetic effects of AngII, or how these
effects relate to AngII wasting. Protein breakdown in
skeletal muscle is predominantly mediated by the UPP
and the autophagy-lysosome system, but the specific
role of autophagy in AngII skeletal muscle wasting is
not known. We originally reported that AngII impaired
AMP-activated protein kinase (AMPK) activation in
muscle, likely via upregulation of protein phosphatase
2C-alpha (PP2Cα) (AngII did not inhibit kinases up-
stream to AMPK), leading to mitochondrial dysfunction
and ATP depletion, and that direct activation of AMPK
with 5-aminoimidazole-4-carboxamide ribonucleoside
(AICAR) prevented AngII wasting [14,16]. The aims
of this study were to determine the mechanistic link
between PP2Cα and AngII wasting and to uncover the
mechanisms involved in AngII-induced mitochondrial
dysfunction and ATP depletion in skeletal muscle.
Methods
In vivo muscle siRNA electroporation
Four separate siRNAs targeted to PP2Cα mRNA
(SureSilencing™ siRNA set, Qiagen/SA Biosciences) were
tested for knockdown efficiency in vivo, by injecting
gastrocnemius (Gas) muscles of ketamine/xylazine anes-
thetized FVB mice (male, 8 to 10 weeks old, Charles River)
with 2.5 μg [24,25] of each siRNA and control scrambled
siRNA in sterile saline at 5 sites using 50 μL Hamilton
syringes with 22 gauge needles, followed by immediate
electroporation of the muscle using a BTX Harvard
Apparatus ECM 830 Electro Square Porator™ with the fol-
lowing settings: 50 V [24,25], 20 ms pulse duration, 0.5 cm
between electrodes, 8 unipolar pulses [25,26], and 1 s
between pulses. The target sequences of the four PP2Cα
siRNAs were as follows: siRNA A - CCAAGATATTTCT
GAGACATT, siRNA B - CCAGATACAAATTACCT
GTTT, siRNA C - CTTGGTGGATGGGCAGATCTT,
and siRNA D - CAAGCTGCAATCATGGAACTT. Afterdetermining the most effective siRNA, it was used for time
course (1, 3, 5, 7, and 11 days) and dose response experi-
ments (vehicle, 2.5 μg, 5 μg, 7.5 μg, 10 μg, 12.5 μg siRNA)
to further optimize target knockdown in Gas in vivo.
Experimental design
In the experimental setting, 5 μg of PP2Cα siRNA and
scrambled siRNA were electroporated into contralateral
Gas muscles (alternating right and left between animals).
Three days later, mice were implanted subcutaneously
with osmotic minipumps (Alzet 1007D) continuously
infusing either sterile saline (control) or 1,000 ng/kg/min
AngII (Phoenix Pharmaceuticals). This dose of AngII
yields a 2.8-fold increase in plasma AngII that is within
the pathophysiological ranges observed in patients with
congestive heart failure (CHF) and chronic kidney dis-
ease [12,14,27-30]. Mice were sacrificed after another
4 days, muscles were collected, weighed, and either used
fresh or embedded in Allprotect Tissue Reagent (Qiagen)
and stored at −80°C until processing. Cryosections were
prepared by incubating Gas muscles in 50% optimal cut-
ting temperature (OCT) compound (Tissue-Tek, USA) for
15 min on ice followed by freezing in 100% OCT. Eight
micron serial cross sections were prepared from the mid-
dle of each muscle and kept at −80°C until processing.
The animal protocols were approved by Tulane University
Institutional Animal Care and Use Committee.
Biochemical assays
Frozen tissue was blotted dry of excess Allprotect reagent
and pulverized with a mortar and pestle over liquid nitro-
gen. Aliquots of each pulverized muscle were prepared as
previously described [14] for mitochondrial quantification
(via DNA isolation followed by real-time PCR using
primers specific for mitochondrial DNA and genomic
DNA), complex IV activity (Mitochondria Activity Assay
Kit, BioChain), ATP quantification (ATP determination kit,
Invitrogen), quantitative real-time RT-PCR (using Qiagen/
SuperArray optimized primers for PP2Cα, p62/SQSTM1,
LC3A, Fbxo32, and Trim63, plus β-actin and HPRT1
housekeeping genes), and SDS-PAGE/western blotting.
Primary antibodies utilized were as follows: from
Abcam: PPM1A (ab14824), PP2C alpha + PP2C beta
(ab27267), PGC-1α (ab54481), Fbxo32 (ab74023), MuRF1
(ab77577), Mitofusin-1, TTC11 (Fis1, ab71498), MARCH5
(ab77585), UCP3 (ab3477), Mitofusin-2 (ab56889), TFAM
(ab131607), OPA1 (ab55772), Mff (ab81127), and Mito-
Profile Total OXPHOS Rodent WB Antibody Cocktail
(Abcam/MitoSciences, ab110413), from Cell Signaling Tech-
nology: p-T172-AMPKα (2531), AMPKα (2532), p-S473-
Akt (4058), p-T308-Akt (5106), Akt (9272), Phospho-Fox01
(Thr24)/Fox03a (Thr32) Antibody (9464), p-S413-Fox03a
(8174), Fox01 (2880), Fox03a (2497), caspase-3 (9662),
cleaved caspase-3 (9664), TCF11/NRF1 (8052), p-S616-
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(3495), LC3A/B (12741), LAMP1 (9091), p-S757-Ulk1
(6888), p-S555-Ulk1 (5869), Ulk1 (8054), SQSTM1/p62
(5114), β-Actin, and α-tubulin (2144), from Enzo: Rpt6
(BML-PW9265).
Immunohistochemistry
Serial skeletal muscle frozen cross sections were stained for
LC3 and p62 using rabbit a/LC3 pAb from MBL Co., Ltd
(Cat# PM036, Japan) or mouse a/SQSTM1/p62 mAb from
Abcam (cat# ab56416, USA), respectively. Sections were
fixed with 4% paraformaldehyde (15 min), treated with
0.1% Triton X-100 in PBS, and stained with primary a/b
for 1 h at room temperature. Biotin-conjugated anti-mouse
(or anti-rabbit) IgG (1:400, Vector Labs, cat# BA2000 and
BA1000, respectively) were applied for sections for 45 min
followed by incubation with streptavidin-Alexa594 conju-
gate (1:500) plus DAPI (both from Invitrogen). Antibody
specificity was verified routinely by staining of serial sec-
tions with ‘normal’ IgG (obtained from an unimmunized
animal of the same species as primary antibody, Santa Cruz
Biotechnology, Santa Cruz, CA, USA). We did not observe
any detectable immunopositivity on ‘normal’ IgG-stained
sections (data not shown).
Statistical analysis
All data are presented as means +/− standard errors
(SEM, n indicated in figure legends and within each in-
dividual group/bar). GraphPad software (Version 6.03
for Windows, GraphPad Software, San Diego, CA, USA)
was used to perform the statistical analysis. Differences
between groups were determined by two-way ANOVA
followed by Holm-Sidak’s multiple comparisons test (for
experiments involving both AngII infusion and siRNA
intervention, as well as for time courses), or by one-way
ANOVA followed by Tukey post-tests (determination of
optimal siRNA target sequence and dose responses with
a single siRNA) as appropriate. A value of P <0.05 was
considered statistically significant.
Results
Knockdown of PP2Cα in vivo
Four days after electroporation, PP2Cα siRNAs B and C
both significantly reduced expression of PP2Cα mRNA in
Gas by approximately 37% (P <0.05), while siRNA A proved
to be the most effective with a 57% reduction (P <0.001) in
mRNA compared to control, and siRNA D failed to reduce
expression of PP2Cα (Figure 1A). A total of 2.5 μg of
PP2Cα siRNA A significantly reduced gene expression from
1 to 7 days post electroporation, with a peak suppression
from baseline of 75% measured at day 3, and returning to
normal by day 11 (Figure 1B). There was a non-statistically
significant trend for transient suppression of PP2Cα mRNA
expression with scrambled siRNA/electroporation, whichreturned to normal between days 3 and 5 (Figure 1B).
Similarly, PP2Cα protein tended to be reduced by PP2Cα
siRNA A throughout the time course, with a significant
reduction of 58% at day 7 (Figure 1C), while AMPK phos-
phorylation was significantly increased at days 1, 5, and 7
(Figure 1D). The dose response performed at day 7 indi-
cated that 5 μg of siRNA was the optimal dose, with a 51%
reduction in expression compared to 31% with 2.5 μg,
while scrambled siRNA did not reduce expression at all
(Figure 1E). PP2Cα protein expression was significantly
reduced at all doses of PP2Cα siRNA (Figure 1F), and
there was a concomitant 2.3-fold increase in AMPK phos-
phorylation with 5 μg of PP2Cα siRNA (Figure 1G).
PP2Cα knockdown prevented AngII skeletal muscle
wasting
AngII-infused mice lost 12.5% of total body mass
(P <0.001) and 26% of Gas mass (P <0.001) compared to
saline-infused controls at day 4 (Figure 2A and B). Two
unique PP2Cα siRNAs significantly rescued the AngII-
induced reduction in Gas mass by approximately 37%
(P <0.001 and P <0.05 respectively, Figure 2B). As an add-
itional control, we measured weights of ipsilateral quadri-
ceps muscles, which were not treated with siRNA. As
expected, there was no rescue in the quadriceps of the legs
receiving either PP2Cα siRNA in Gas (Figure 2C). AngII
also reduced average cross sectional area of individual Gas
muscle fibers (Figure 2D) and induced a frequency shift
towards smaller fibers (Figure 2E), and PP2Cα siRNA
prevented the AngII-induced reductions in fiber size
(Figure 2D and E).
PP2Cα knockdown restored AMPK activation and PGC-1α
expression to activate mitochondrial biogenesis
Infusion of AngII caused a 46% increase in PP2Cα protein
expression (P <0.0001), consistent with our previous find-
ings [14], and two separate PP2Cα siRNAs significantly
reduced basal PP2Cα expression and blocked the AngII-
mediated increase (down to a 13% increase, P <0.001 and
P <0.05 respectively, Figure 3B). Consistent with increased
PP2Cα expression, AngII reduced activating T172 AMPK
phosphorylation by 37% (P <0.05, Figure 3C), and PP2Cα
knockdown with two unique siRNAs increased AMPK
phosphorylation by 2-fold and 1.8-fold respectively com-
pared to scrambled siRNA (Figure 3C). Active AMPK in-
creases expression of PGC-1α, which is a critical mediator
of mitochondrial biogenesis, increasing the expression of
transcription factors NRF1 and TFAM, which coordinate
expression of mitochondrial genes and are critical for
transcription of mitochondrial DNA (mtDNA) [31-33].
PGC-1α expression was reduced by 29% with infusion of
AngII (P <0.001, Figure 3D), with a near complete res-
cue by PP2Cα knockdown using two separate siRNAs









Figure 1 In vivo knockdown of PP2Cα. The indicated siRNAs were injected at five sites in Gas muscles which were then electroporated to
induce uptake of the siRNA. The most effective sequence, time point, and dose of siRNA were chosen for subsequent AngII-infusion experiments.
(A) Real-time PCR showing PP2Cα mRNA knockdown in Gas using 2.5 μg of four different PP2Cα siRNA target sequences relative to negative
control siRNA at day 4 post electroporation. PP2Cα siRNA ‘A’ was used in all time course and dose response experiments. (B) Time-course of
PP2Cα mRNA knockdown in Gas with 2.5 μg of scrambled and PP2Cα siRNA. (C) Time-course of PP2Cα protein knockdown in Gas with 2.5 μg of
scrambled and PP2Cα siRNA. (D) Time-course of AMPK phosphorylation in Gas with 2.5 μg of scrambled and PP2Cα siRNA. (E) Dose response of
PP2Cα mRNA knockdown in Gas at day 7 post electroporation. (F) Dose response of PP2Cα protein knockdown in Gas at day 7 post electroporation.
(G) Dose response of AMPK phosphorylation in Gas at day 7 post electroporation. (H) Representative western blots showing PP2Cα protein knockdown
and AMPK activation with 5 μg of PP2Cα siRNA at day 7. n =4-8 per group, Mean ± SEM, *P <0.05, **P <0.01, ***P <0.001.
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reduced TFAM (Figure 3F), while PP2Cα knockdown sig-
nificantly increased expression of both NRF1 (Figure 3E)
and TFAM (Figure 3F). Together, these results indicate
that knockdown of PP2Cα prevented the AngII-mediated
suppression of mitochondrial biogenesis.
PP2Cα siRNA-mediated rescue of AngII wasting is
independent of the Akt-FOXO signaling axis
Although AngII greatly reduced activating S473 and T308
Akt phosphorylation (by 87% and 67%, respectively,P <0.001, Figure 4A and B), as well as downstream
Akt-mediated FoxO1/FoxO3a phosphorylation (by 61%,
P <0.001, Figure 4C), PP2Cα knockdown did not reverse
those reductions, and had no effect on basal Akt and
FOXO phosphorylation. Consistent with Akt and FOXO
phosphorylation status, AngII also significantly increased
gene expression of the E3 ubiquitin ligases atrogin-1
(Figure 4E), and MuRF1 (Figure 4F), while also increasing
expression of atrogin-1 protein (Figure 4G), but not
MURF1 protein (Figure 4H). PP2Cα knockdown did not
significantly reduce AngII-mediated induction of E3 ligase
A B C 
D E 
Figure 2 PP2Cα knockdown prevented AngII wasting. A total of 5 μg of the indicated siRNA sequences were injected at five sites in Gas
muscles which were then electroporated to induce uptake of the siRNA. Three days later, osmotic minipumps were implanted subcutaneously
and continually infused either saline or 1,000 ng/kg/min AngII for another 4 days. (A) Total body mass showing whole-body AngII wasting over
4 days of continuous infusion. (B) Gastrocnemius wet weight showing AngII muscle wasting and rescue with PP2Cα knockdown at 4 days. Two
PP2Cα siRNA target sequences (A and B, Figure 1A) were tested to verify the specificity of the rescue effect. (C) Quadriceps wet weight showing
AngII muscle wasting after 4 days. Quadriceps were not treated with siRNA, so quadriceps muscles ipsilateral to Gas receiving PP2Cα siRNA
showed no rescue effect. (D) Average cross sectional area of Gas muscle fibers infused with either saline or AngII and treated with either
scrambled or PP2Cα siRNA ‘A’. (E) CSA frequency distribution curves of Gas muscle fibers. n =6-32 per group, Mean ± SEM, **P <0.01, ***P <0.001,
****P <0.0001 (Saline scrambled vs. AngII scrambled), +P <0.05, +++P <0.001 (AngII scrambled vs. AngII PP2Cα siRNA).
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two E3 ligases (Figure 4E-H). Further, phosphorylation at
S413-FOXO, which is mediated by AMPK was not altered
with AngII or PP2Cα knockdown (Figure 4D). Since
knockdown of PP2Cα did not prevent Akt inhibition,
FOXO activation, and increased expression of atrogin-1 or
MURF1 by AngII, other pathways must be involved in the
ability of PP2Cα knockdown to reduce AngII-induced
wasting.
PP2Cα knockdown increased mitochondrial content and
ameliorated AngII-induced mitochondrial dysfunction
We have previously shown that AngII reduced skeletal
muscle ATP levels, which could be prevented by activat-
ing AMPK with AICAR [14]. Therefore, we analyzed
parameters of mitochondrial content and function with
PP2Cα knockdown. There was no observed change in
the expression of uncoupling protein-3 (UCP3), or of
electron transport chain complexes I-IV with AngII orPP2Cα knockdown (Figure 5A-E), but AngII reduced
ATP-synthase (complex V) expression by 68% (P <0.0001,
Figure 5G), and PP2Cα siRNA did not restore complex V
expression to normal (Figure 5F). Although AngII did not
alter mitochondrial copy number compared to control,
knockdown of PP2Cα increased basal mitochondrial con-
tent by 98% and by 46% in AngII infused Gas compared to
scrambled siRNA, consistent with the trends observed in
expression of PGC-1α (P <0.05, Figure 5G).
Expression of cytochrome C oxidase (complex IV) was
not reduced (if anything there was a trend for increased
expression with AngII, Figure 5E), but complex IV activity
was reduced by 70% with AngII (P <0.0001), and PP2Cα
knockdown partially blocked the effect of AngII such that
complex IV activity was reduced by only 48% (P <0.05,
Figure 5H). Quantification of ATP in Gas revealed a paral-
lel trend, with a 74.5% reduction with AngII (P <0.0001),
which was partially inhibited to a 49% reduction by PP2Cα

















Figure 3 PP2Cα knockdown restored AMPK activation and signaling related to mitochondrial biogenesis. Specificity was ensured by
performing experiments with two siRNA target sequences, as indicated. (A) Representative western blots showing effects of AngII and PP2Cα
siRNA ‘A’ on the AMPK-PGC-1α-TFAM signaling axis. (B) PP2Cα protein expression was increased with AngII, which was prevented with PP2Cα
siRNA. (C) Activating AMPK phosphorylation was reduced with AngII and increased with PP2Cα knockdown. (D) PGC-1α protein expression was
reduced with AngII, which was prevented with PP2Cα siRNA. (E) PP2Cα siRNA increased expression of NRF1 transcription factor. (F) AngII reduced
expression of the mitochondrial transcription factor TFAM, and this reduction was prevented by PP2Cα siRNA. n =4-32 per group, Mean ± SEM,
*P <0.05, **P <0.01, ****P <0.0001 (Saline scrambled vs. AngII scrambled), +P <0.05, +++P <0.001 (AngII scrambled vs. AngII PP2Cα siRNA).
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sence of AngII.
Prolonged mitochondrial dysfunction and bioenergetic
stress can lead to initiation of apoptosis, which is charac-
terized by caspase-3 release and activation [34,35], and
activation of caspase-3 is known to be required for AngII
wasting [4,17]. Expression of total caspase-3 did not
change with AngII or PP2Cα knockdown, but 17KDa
cleaved activated caspase-3 was increased 3.4-fold with
AngII (P <0.0001) and PP2Cα siRNA reduced that in-
crease to only 1.6-fold, while not changing basal caspase
activation (P <0.001, Figure 6A). Because caspase-3 activa-
tion has been linked to proteasome activation via cleavage
of the 19S regulatory cap ATP-ase Rpt6 [17], we also
assessed Rpt6 cleavage with AngII and PP2Cα knockdown.
AngII increased Rpt6 cleavage by 2-fold without altering
total Rpt6 expression (P <0.05), and that increased cleav-
age was blunted by PP2Cα siRNA (P <0.05, Figure 6B).PP2Cα knockdown in saline controls had no effect on
Rpt6 cleavage. Ubiquitin-conjugated proteins were also in-
creased with AngII, indicating an increase in substrates for
the proteasome, while this increase tended to be reduced
with PP2Cα knockdown but did not approach significance
(Figure 6C).
Collectively, these data indicate that AngII caused pro-
found mitochondrial dysfunction without significantly al-
tering total mitochondrial load, while also implicating
activation of the proteasome. Mitochondrial copy number
is coordinated simultaneously by mitochondrial biogenesis
and mitochondrial turnover via mitophagy. As such, the
fact that AngII did not alter mitochondrial content com-
pared to control while significantly inhibiting pathways
critical to mitochondrial biogenesis implicates an effect of
AngII on autophagy/mitophagy. AngII-induced mitochon-
drial dysfunction was associated with activation of apop-




















Figure 4 PP2Cα knockdown did not restore AngII-mediated reductions in Akt or Fox0 phosphorylation or increased E3 ubiquitin ligase
expression. All data were generated from experiments utilizing PP2Cα siRNA ‘A’. (A, B) Activating Akt phosphorylation was reduced with AngII,
but not rescued by PP2Cα knockdown. (C) Akt-mediated inhibitory Fox0 phosphorylation was reduced with AngII, but not rescued by PP2Cα
knockdown. (D) AMPK-mediated phosphorylation of FOXO3a was not altered by AngII or PP2Cα knockdown. (E) Expression of atrogin-1 mRNA
was upregulated by AngII, but not rescued by PP2Cα knockdown. (F) Expression of MURF1 mRNA was upregulated by AngII, but not rescued by
PP2Cα knockdown. (G) Expression of atrogin-1 protein was upregulated by AngII, but not rescued by PP2Cα knockdown. (H) No change in MURF1
protein expression was detected with AngII or PP2Cα siRNA. (I) Representative western blots showing effects of AngII and PP2Cα siRNA ‘A’ on the Akt-
FOXO-E3 ligase signaling axis. n =6-20 per group, Mean ± SEM, *P <0.05, ***P <0.001 (Saline scrambled vs. AngII scrambled), +P <0.05 (AngII scrambled
vs. AngII PP2Cα siRNA).
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induced mitochondrial dysfunction, caspase-3 activation,
and Rpt6 cleavage.
PP2Cα siRNA prevented AngII-mediated inhibition of
autophagy
Healthy mitochondrial function is preserved by balancing
mitochondrial biogenesis and recycling via mitophagy.
Since AngII reduced PGC-1α without reducing total mito-
chondrial load in Gas, this indicated a potential impair-
ment in mitophagy. To evaluate the role of autophagy in
AngII-mediated mitochondrial dysfunction and wasting,
we quantified several autophagy markers, including p62
accumulation, beclin-1 expression, and LC3-II conversion.Expression of p62 protein was increased by 2.4-fold with
AngII (P <0.0001), and PP2Cα siRNA blunted that in-
crease to 1.5-fold, while not altering basal p62 (P <0.05,
Figure 7A and B), and neither AngII nor PP2Cα siRNA
had any effect on transcription of p62 (Figure 7H), indicat-
ing an inhibition of autophagic flux with AngII and pre-
vention of that inhibition with knockdown of PP2Cα. This
is corroborated by the 2.8-fold increase in LC3-II con-
version with PP2Cα knockdown over AngII alone, indica-
tive of increased mature autophagosome formation with
PP2Cα knockdown (P <0.05, Figure 7A and C). LC3A
mRNA expression (Figure 7I) was not significantly altered
by either AngII or PP2Cα siRNA, indicating that the in-

















Figure 5 PP2Cα knockdown increased mitochondrial content and partially restored AngII-induced mitochondrial dysfunction. All data
were generated from experiments utilizing PP2Cα siRNA ‘A’. (A) UCP-3 expression, (B) NADH dehydrogenase (complex I) expression, (C) succinate
dehydrogenase (complex II) expression, (D) cytochrome bc1 complex (complex III) expression, and (E) cytochrome C oxidase (complex IV)
expression were not altered by AngII or PP2Cα siRNA. (F) AngII reduced ATP synthase (complex V) expression, which was not restored with PP2Cα
siRNA. (G) Relative mitochondrial copy number was unaltered by AngII, but PP2Cα siRNA increased mitochondrial load. (H) Complex IV (Cytochrome
C Oxidase) activity was reduced with AngII and partially restored with PP2Cα knockdown. (I) ATP was reduced with AngII and partially restored with
PP2Cα knockdown. (J) Representative western blots showing expression of ETC., complexes I-V, and uncoupling protein-3. n =6-20, Mean ± SEM,
***P <0.001 (Saline scrambled vs. AngII scrambled), +P <0.05 (AngII scrambled vs. AngII PP2Cα siRNA).
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scription of LC3.
Western blot data for p62 were verified by immuno-
fluorescence on Gas cross sections showing an increase
in p62-positive punctae with AngII and a reduction
compared to AngII alone with knockdown of PP2Cα
(Figure 7J). Further, PP2Cα siRNA increased the num-
ber LC3A-positive punctae compared to AngII alone
(Figure 7K), indicating a greater number of autophago-
somes with knockdown of PP2Cα in AngII-infused Gas.
PP2Cα siRNA had no obvious effect on the number of
p62 or LC3A-positive punctae in saline infused controls
(Figure 7J and K). PP2Cα siRNA also increased expres-
sion of beclin-1 by 2.8-fold (P <0.05, Figure 7A and D),
further supporting increased autophagy with PP2Cα
knockdown, while AngII reduced expression of thelysosome marker lysosomal-associated membrane protein
1 (LAMP1) indicating that there may be a reduction in
the number of lysosomes with AngII, but this reduction
was not prevented by PP2Cα siRNA (Figure 7A and E).
Given the observed changes in autophagy markers,
ULK1 phosphorylation status was ascertained to obtain
potential insights into mechanisms. ULK1 is an upstream
mediator of autophagosome formation that is critical for
autophagy, and its activity is known to be regulated by
AMPK [36-39]. AngII reduced activating S555 phosphor-
ylation of ULK1 by 39% (P <0.05), and this effect was
completely reversed by PP2Cα siRNA (P <0.05, Figure 7F).
Inhibitory S757 phosphorylation of ULK1 was increased
by 86% with AngII (P <0.01), and this increase was also
almost completely reversed by knockdown of PP2Cα























Figure 6 PP2Cα knockdown prevented caspase-3 activation and Rpt6 cleavage. All data were generated from experiments utilizing PP2Cα
siRNA ‘A’. (A) 17 KDa activated caspase-3 was increased by AngII, and this increase was prevented by PP2Cα knockdown. (B) The proteasome 19S
cap ATP-ase Rpt6 (a target of caspase-3) cleavage was increased with AngII, and this cleavage was blunted by PP2Cα knockdown. (C) Ubiquitin-
conjugated protein was increased with AngII, but not significantly reduced by PP2Cα siRNA. n =6-32 per group, Mean ± SEM, *P <0.05, ****P <0.0001
(Saline scrambled vs. AngII scrambled), +P <0.05, +++P <0.001 (AngII scrambled vs. AngII PP2Cα siRNA).
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fusion and fission via AMPK and MARCH5-indepentdent
mechanisms
Mitofusin-2 and Optic Atrophy 1 (OPA1) facilitate fu-
sion of the outer and inner mitochondrial membranes,
respectively. Mitochondrial fission is mediated by mito-
chondrial fission 1 protein (Fis1), mitochondrial fission
factor (Mff ), and dynamin-1-like protein (DRP1). Inter-
estingly, Mitofusin-2, OPA1, Fis1, and DRP1 expression
were all reduced by Ang II, indicating that Ang II
inhibits both mitochondrial fusion and fission. AngII
markedly reduced expression of mitofusin-2 (83% de-
crease, P <0.0001), although PP2Cα siRNA did not blunt
this decrease (Figure 8A and B). Similarly, AngII also
reduced expression of OPA1 by 68% (P <0.01) and
knockdown of PP2Cα did not prevent this reduction
(Figure 8A and C). AngII reduced expression of Fis1 by
33% (P <0.05, Figure 8A and D) and of DRP1 by 57%
(P <0.05, Figure 8A and F), while PP2Cα knockdown did
not prevent these reductions (Figure 8A,D,F). PP2Cα
knockdown in saline-infused controls had no effect on
expression of mitofusin-2, OPA1, DRP1, or Fis1 (Figure 8A-
D,F). Neither AngII nor PP2Cα knockdown had any effect
on expression of Mff (Figure 8G). DRP1 facilitates mito-
chondrial fission both via changes in expression and phos-
phorylation status [40], and while PP2Cα siRNA had no
effect on total DRP1 expression, it significantly increased
activating DRP1 phosphorylation in AngII-infused Gas(Figure 8A and E). Expression of membrane-associated
RING-CH5 (MARCH5), an E3 ubiquitin ligase known
to regulate both mitofusin-2 and Fis1 [41,42], was signi-
ficantly reduced by AngII (Figure 8A and H), indicating
that some other mechanism must be responsible for the re-
ductions in mitofusin-2 and Fis1 with AngII. MARCH5 ex-
pression was not significantly altered by PP2Cα knockdown
in saline or AngII-infused groups (Figure 8A and H).
Discussion
Our results indicate that PP2Cα is a critical mediator of
AngII wasting. Knockdown of PP2Cα via electroporation
of siRNA into Gas partially prevented AngII wasting,
which is consistent with activation of AMPK being pro-
tective against wasting caused by AngII, as we have pre-
viously demonstrated [14]. Although there are technical
limitations of siRNA electroporation into the skeletal
muscle (that is, electroporation efficiency and siRNA ef-
fectiveness on PP2Ca mRNA), our PP2Ca knockdown
significantly prevented Ang II wasting in vivo. Still, some
components of AngII-wasting are PP2Cα/AMPK-inde-
pendent, or at least indirectly related, which may explain
the partial rescue. We also demonstrate that the meta-
bolic effects of AngII are critical, as PP2Cα knockdown
did not significantly alter the effects of AngII on Akt,
FOXO, or expression of E3 ubiquitin ligases atrogin-1 or
MURF1. This indicates that something other than the




















Sal SCR Sal PP2C
AngII SCR AngII PP2C
Sal SCR Sal PP2C
AngII SCR AngII PP2C
p62 LC3A
Figure 7 AngII inhibited autophagy while PP2Cα knockdown activated it via ULK1. (A) Representative western blots showing effects of
AngII and PP2Cα siRNA on markers of autophagy. (B) AngII increased p62 accumulation (indicative of an inhibition of autophagy) and
knockdown of PP2Cα prevented p62 accumulation. Specificity of the rescue was verified via utilization of two PP2Cα siRNAs, as indicated. All
other data were generated from experiments utilizing PP2Cα siRNA ‘A’. (C) LC3-II conversion was increased with AngII, but increased further by
PP2Cα knockdown. (D) PP2Cα siRNA increased expression of the autophagy marker Beclin-1. (E) AngII reduced expression of the lysosome marker
LAMP1, but this reduction was not restored by PP2Cα siRNA. (F) AngII decreased activating ULK1 phosphorylation, which was prevented by
PP2Cα siRNA. (G) AngII increased inhibitory ULK1 phosphorylation, which was prevented by PP2Cα siRNA. (H, I) There was no transcriptional
regulation of p62 (H), or LC3A (I) with either AngII or PP2Cα siRNA. (J) Representative immunohistochemical images showing the AngII-mediated
increase in p62-positive punctae, and the prevention of that increase via knockdown of PP2Cα, showing inhibition of autophagy with AngII and
restoration of autophagic flux with PP2Cα knockdown. (K) Representative immunohistochemical images showing PP2Cα siRNA increased autophagosome
number as determined by LC3-positive punctae. n =4-20, Mean ± SEM, *P <0.05, **P <0.01, ****P <0.0001 (Saline scrambled vs. AngII scrambled), +P <0.05
(AngII scrambled vs. AngII PP2Cα siRNA).
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chondrial function, ATP, and muscle wasting. Finally, we
have uncovered novel mechanisms linking elevated AngII
to mitochondrial dysfunction in skeletal muscle. These
mechanisms are both AMPK-dependent (reduced mito-
chondrial biogenesis via reduction in PGC-1α/TFAM, and
inhibition of mitophagy via inhibition of ULK1), and
AMPK-independent (reductions in expression of import-
ant regulators of mitochondrial network dynamics).
Certainly, the UPP is very important for AngII wast-
ing, and we have previously shown that AngII-mediated
effects on Akt/FOXO phosphorylation and upregulation
of atrogin-1 and MURF1 mRNA was prevented by directAMPK activation with AICAR [14]. It is important to
point out that the experimental model in the present study
may have some differences from our previously published
work in that injection and electroporation of Gas muscles
represents significant injury to the muscle, and may have
induced the muscle’s normal regenerative responses inde-
pendent of AngII and/or PP2Cα knockdown. Even so,
while knockdown of PP2Cα did not significantly rescue
from AngII-induced upregulations of atrogin-1, MURF1,
and ubiquitin-conjugated proteins, there was a trend for a
reduction in each of these endpoints, although these
trends remain independent of the Akt-FOXO signaling


















Figure 8 AngII inhibited expression of mitochondrial fission and fusion proteins via a MARCH5-independent mechanism. All data were
generated from experiments utilizing PP2Cα siRNA ‘A’. (A) Representative western blots showing effects of AngII and PP2Cα siRNA on markers of
mitochondrial fusion and fission. (B) AngII reduced Mitofusin-2 expression, which was not prevented by PP2Cα knockdown. (C) AngII reduced
OPA1 expression, which was not prevented by PP2Cα knockdown. (D) AngII reduced Fis1 expression, which was not prevented by PP2Cα
knockdown. (E) S616 phosphorylation of DRP1 was increased with PP2Cα siRNA, which facilitates mitochondrial fission. (F) DRP1 expression was
reduced by AngII, and this was not rescued by PP2Cα knockdown. (G) Mff expression was not altered by AngII or PP2Cα siRNA. (H) MARCH5
expression was not induced with AngII and was unchanged by PP2Cα siRNA. n =4-20, Mean ± SEM, *P <0.05, **P <0.01, ***P <0.001 (Saline
scrambled vs. AngII scrambled), +P <0.05 (AngII scrambled vs. AngII PP2Cα siRNA).
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on the UPP, but we have clearly shown that many of the ef-
fects of AngII on mitochondrial dysfunction are dependent
on AMPK.
As AMPK is activated, PGC-1α expression increases, in
turn activating a program of mitochondrial biogenesis
[31,32]. As such, AngII’s effect to suppress AMPK phos-
phorylation and expression of PGC-1α/NRF1/TFAM in
skeletal muscle impairs generation of new mitochondria.
The deleterious effects of AngII on mitochondrial biogen-
esis are reflected by AngII’s marked suppression of mito-
chondrial ATP synthase (complex V) expression, complex
IV activity, and ATP generation in Gas. Conversely, the
ability of PP2Cα knockdown to increase PGC-1α, NRF1,
and TFAM expression acts in opposition to AngII by fa-
cilitating mitochondrial biogenesis and PP2Cα siRNA par-
tially restored mitochondrial activity and ATP toward
basal levels, while significantly increasing mitochondrial
copy number.
Healthy mitochondrial function is normally maintained
both by generation of new mitochondria via PGC-1α-
NRF1-TFAM-mediated biogenesis, and by sequestrationof damaged or defective mitochondria to autophagosomes
and their subsequent degradation following fusion to lyso-
somes in a process known as mitophagy [43,44]. The spe-
cificity of mitophagy is mediated via mitochondrial fission
and fusion, as well as by several mitophagy proteins, in-
cluding p62, which binds ubiquitinated mitochondrial pro-
teins and LC3 on the autophagosome to facilitate selective
degradation of damaged mitochondria [44,45]. Because
p62 is normally degraded along with the rest of the com-
ponents of the autophagosome, its accumulation in the
absence of transcriptional regulation indicates an inhib-
ition of autophagy [44].
AngII significantly increased p62 protein without alter-
ing mRNA levels, indicating impairment of autophagy.
While p62 clearance/accumulation is a reasonable index
of autophagic flux in the absence of transcriptional regu-
lation, it will be informative to measure flux directly in
future studies, for instance by tracking LC3 turnover
alongside p62 accumulation [46]. The partial restoration
of p62 to basal levels, along with increased expression of
Beclin-1 and conversion of LC3-II with PP2Cα knock-
down, indicates that AngII decreased autophagy via
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early step in autophagosome formation and a higher
ratio of LC3-II to LC3-I indicates a greater number of
autophagosomes and usually indicates an induction of
autophagy, although increased LC3 expression and con-
version can also indicate an inhibition of downstream
autophagic processes [47]. Because AngII appeared to
reduce the expression of the lysosome marker LAMP1,
the increased LC3-II conversion with AngII compared to
baseline may implicate such a downstream inhibition in
addition to the upstream effects on ULK1. Given that
AngII increased p62 accumulation while leaving beclin-1
expression unchanged, the AngII-mediated increase in
LC3-II conversion over control likely does not indicate
an activation of autophagy over basal rates. Indeed, while
it did not reach statistical significance, there appears to
be a modest trend for increased LC3A gene expression
with AngII, which may also explain the increase in LC3-
II conversion over basal conditions with AngII. Knock-
down of PP2Cα in the presence of AngII further
increased LC3-II conversion, but reduced p62 and also
increased beclin-1, indicating that AngII-mediated inhib-
ition of AMPK inhibited autophagy.
Failure of the cell to clear damaged mitochondrial pro-
teins results in the accumulation of dysfunctional mito-
chondria and a reduced ability to meet cellular energetic
demands. This deficit is accentuated in our model (where
AMPK activation is impaired by AngII) because AMPK
activation is the normal physiologic response to decreased
ATP availability. Although AMPK activation can be asso-
ciated with mitochondrial dependent muscle wasting, and
inhibition of AMPK has been shown to restore muscle
size in myofibers with altered mitochondria [45], the op-
posite appears to be the case with regards to wasting
caused by AngII [14].
In the current study, p62 accumulation with AngII indi-
cates impairment in the rate of autophagy. This is corrob-
orated by the accumulation of dysfunctional complex IV
in AngII-infused muscle, as demonstrated by the marked
reduction in complex IV activity, even while total complex
IV expression tended to increase. The accumulation of
dysfunctional mitochondria is reflected in the reduction of
ATP in response to AngII while mitochondrial load
remained unchanged. Activation of AMPK signaling via
knockdown of PP2Cα acted in opposition to AngII by
facilitating autophagy as evidenced by reduced p62 accu-
mulation, and improved mitochondrial function as indi-
cated by increased complex IV activity, and increased
ATP. Further, the degree to which PP2Cα siRNA activated
mitochondrial biogenesis outweighed the degree to which
mitophagy was activated since total mitochondrial content
was increased by knockdown of PP2Cα. As such, the
net effect of PP2Cα knockdown during infusion of
AngII is a greater number of total mitochondria and asimultaneously higher proportion of fully functional,
more efficient mitochondria, leading to increased en-
ergy production and protection from AngII wasting.
ULK1 is a critical mediator of autophagy [36-39], acting
at the most upstream stages of nucleation and initial
autophagosome formation. The ULK1 complex is differen-
tially activated and inhibited by AMPK and mTORC1, re-
spectively [36-39,44,47]. AngII reduced activating ULK1
phosphorylation, while simultaneously inducing inhibitory
ULK1 phosphorylation in Gas, effects which are likely me-
diated, at least in part, by AngII’s inhibitory effects on
AMPK in muscle, and which serve to inhibit autophagy in
muscle. Activation of AMPK via knockdown of its phos-
phatase PP2Cα alleviated the inhibitory effect of AngII on
AMPK and restored ULK1 phosphorylation status to basal
levels, in turn restoring autophagic flux to normal levels.
The ability of PP2Cα knockdown to oppose the inhibitory
effects of AngII on ULK1 activation is consistent with a
mechanism whereby AngII impairs autophagy and AMPK
acts in opposition to activate it in skeletal muscle.
Parallel to its inhibitory effects on the PGC-1α-NRF1-
TFAM axis (mitochondrial biogenesis), ULK1 (autophago-
some formation), and p62 clearance (autophagic flux),
AngII also significantly reduced expression of several
markers of mitochondrial fusion (mitofusin-2, OPA1) and
fission (Fis1, DRP1), suggesting that AngII also acts to in-
hibit both mitochondrial fusion and mitochondrial fission.
Mitofusin-2 is located on the outer mitochondrial mem-
brane, while OPA1 is localized to the inner mitochondrial
membrane and both are critical for the initiation of mito-
chondrial fusion [41,44,48]. Fusion of mitochondria into
complex networks helps to increase overall mitochondrial
efficiency by compensating for damaged or dysfunctional
oxidative phosphorylation machinery and tends to be in-
duced during times of high energetic demand [44]. There-
fore, inhibition of mitochondrial fusion by AngII would
prevent the muscle from compensating for the deleterious
effects of AngII on energy balance, and could play a role in
ATP depletion with AngII. Fis1 and Mff are localized to
the outer mitochondrial membrane, while DRP1 associates
with these proteins to form a complex which facilitates
fission of the mitochondrial network [40-42,48]. Both
DRP1 expression and activity are important for mitochon-
drial fission, and its activity is modulated via phosphoryl-
ation by several upstream kinases including Cdk1/cyclin B,
and protein kinase A [49]. Mitochondrial fission is import-
ant because it allows the cell to group damaged mitochon-
drial components together so that they can be selectively
recycled via mitophagy (thereby leaving functioning mito-
chondria intact). The ability of AngII to reduce Fis1 and
DRP1 expression may further facilitate AngII-impairment
of selective mitophagy and could also help explain the
build-up of damaged mitochondrial proteins and energy
depletion in response to AngII, while increased activating
Figure 9 Proposed model whereby AngII infusion leads to mitochondrial dysfunction and skeletal muscle wasting. Parallel to the
well-characterized AngII-mediated activation of the FOXO-E3-UPS axis via inhibition of Akt, AngII also induces expression of the phosphatase
PP2Cα, which dephosphorylates and inactivates AMPK. This leads to reduced PGC-1α, NRF1, and TFAM expression (less mitochondrial biogenesis),
and reduced ULK1 activity. The AngII-mediated reduction in ULK1 activation inhibits a critical early step in the autophagy pathway and prevents
recycling of damaged mitochondria (mitophagy). AngII also inhibits both mitochondrial fission and fusion through predominately AMPK-independent
pathways, which likely contribute to mitochondrial dysfunction caused by elevated AngII. Prolonged mitochondrial dysfunction and energy depletion
ultimately leads to release of caspase-3, initiation of apoptosis, and wasting.
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position to facilitate fission and selective mitophagy.
MARCH5 is an E3 ligase that regulates the expression
of both mitofusin-2 and Fis1 via UPP-mediated degrad-
ation of these proteins [41]. Its expression is not signifi-
cantly increased with AngII. In fact, MARCH5 expression
was significantly reduced by AngII, making it unlikely
that MARCH5 mediates the AngII-induced reductions in
mitofusin-2 and Fis1. Further, knockdown of PP2Cα re-
versed the effects of AngII on PGC-1α and autophagy, but
did not reverse the effects of AngII on mitofusin-2, OPA1,
DRP1, or Fis1 expression, suggesting that AMPK is not
directly involved in mediating the expression of these pro-
teins, and that the ability of PP2Cα knockdown to improve
mitochondrial recycling is primarily through restoration of
ULK1 activity and autophagosome formation rather than
via alterations in mitochondrial fission/fusion. Still, the
overall relationship between AngII, AMPK, and the dy-
namic remodeling of the mitochondrial network will re-
quire further studies, since PGC-1α [50,51] and FOXO3a
[44] have been shown to play a role in mitochondrialfusion and fission, respectively, and both are known to be
regulated by AMPK.
Conclusions
Our data show that AngII-mediated skeletal muscle wast-
ing is characterized by impairment of mitochondrial bio-
genesis, fission, fusion, and autophagy, thereby preventing
normal mitochondrial recycling and leading to mitochon-
drial dysfunction, ATP depletion, and wasting (summa-
rized in Figure 9). Further, we have shown that AngII
wasting and its effects on mitochondrial function are me-
diated at least in part via upregulation of PP2Cα in muscle.
Thus, our studies elucidate novel mechanisms underlying
AngII wasting and suggest a therapeutic potential for acti-
vators of AMPK in wasting conditions where the renin-
angiotensin system is activated.
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